Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5241]

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant...

Prof Nicolas Girard - Institut Curie, Paris, France

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

Distinct lung microbiome patterns identified in Portuguese patients with lung...

Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal

Distinct lung microbiome patterns identified in Portuguese patients with lung cancer ( Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal )

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities ( Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea )

Education and training in breast cancer care

Dr Alexandru Eniu, Danny Burke & Dr Montassar Ghalleb

Education and training in breast cancer care ( Dr Alexandru Eniu, Danny Burke & Dr Montassar Ghalleb )

Cracking the code: Bispecific immunotherapy in small cell lung cancer

Prof Helena Linardou - Metropolitan Hospital, Athens, Greece

Cracking the code: Bispecific immunotherapy in small cell lung cancer ( Prof Helena Linardou - Metropolitan Hospital, Athens, Greece )

ATR inhibitor plus durvalumab does not improve survival over docetaxel in...

Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC ( Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France )

Durvalumab after SBRT reduces tumour progression in early-stage NSCLC

Dr Andreas Hallqvist - Sahlgrenska University Hospital, Göteborg, Sweden

Durvalumab after SBRT reduces tumour progression in early-stage NSCLC ( Dr Andreas Hallqvist - Sahlgrenska University Hospital, Göteborg, Sweden )

Gotistobart improves survival and response over docetaxel in previously treated...

Dr Kai He - The Ohio State University Comprehensive Cancer Center, Columbus, USA

Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer ( Dr Kai He - The Ohio State University Comprehensive Cancer Center, Columbus, USA )

Rituximab-based chemotherapy achieves strong outcomes without routine...

Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma ( Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany )

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic...

Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer ( Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA )

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise...

Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care ( Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte )

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer